U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive … – AbbVie
- Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant therapy (ADT), showing improvement…